According to information from The Fly, the price target that Wedbush has established for G1 Therapeutics (NASDAQ: GTHX) has increased from twenty dollars to twenty-five dollars as a result of a research report that was released on Friday. According to the target price that Wedbush has assigned to the stock, there is the potential for a price increase of 61.81 percent higher than where it is currently trading. Additional studies into GTHX have been conducted in significant quantities. In a research note on the company’s stock published on Friday, June 3rd, HC Wainwright maintained their “buy” rating on shares of G1 Therapeutics and established a price objective of $67.00. This information was included in the research note.
Needham & Company LLC lowered their price objective for G1 Therapeutics in a research report published on Thursday, August 4th. Despite this change, the firm continued to provide the company with a “buy” recommendation on the stock. Five market analysts have provided the stock with a recommendation to buy, while one analyst has suggested selling the shares. According to data from Bloomberg.com, the stock is currently rated as having a consensus recommendation of “Moderate Buy,” with a price target of $36.83 on average. G1 Therapeutics was trading at a share price of $15.45 when the day’s trading session started on Friday.
The company has traded at an average price of $11.41 per share over the past 50 trading days, while its price has been $8.16 per share on average over the last 200 trading days. The firm’s market capitalization is currently sitting at $660.49 million, while its price-to-earnings ratio is at-3.85 and its beta stands at 1.93. There is debt equal to 1.15 times the amount of equity, current assets equal to 4.75 times equity, and liquid assets equal to 4.38 times equity. The stock price of G1 Therapeutics hit a low of $3.84 during the prior year, while it reached a high of $17.49 during that same period.
On Wednesday, August 3rd, the most recent quarterly results report for G1 Therapeutics (NASDAQ: GTHX) was made available to the public. The company’s earnings per share for the quarter came in at $0.92, which was $0.12 higher than the experts’ average forecast of $1.04, which analysts had supplied. Both the net margin and the return on equity for G1 Therapeutics were in the red. The net margin was -608.36%, and the return on equity was -140.17%. The sales for the company came in at $10.57 million for the quarter, which is much more than the average prediction of $9 million, which analysts made. According to the general opinion held by market analysts, G1 Therapeutics will report a loss of -3.51 cents per share for the current fiscal year.
The sale of 80,000 shares of the company’s stock by Director Mark A. Velleca on August 16th brings us to another piece of news regarding G1 Therapeutics. It was established that the stock was sold at $12.64 per share, which resulted in a total transaction volume of $1,011,200.00. The stock was sold at a price determined to be the average price. The director is now the happy owner of 116,000 shares of the company’s stock, which have an approximate value of 1,466,240 dollars as a direct result of the transaction. Following the link that has been supplied will take you to the legal file kept by the Securities and Exchange Commission (SEC). In this file, you will find information on the transaction that has been kept there. The current percentage of the company’s stock that insiders own is 8.09%.
In recent months, institutional investors, such as hedge funds, have either expanded or cut their stakes in the company, depending on the path they chose to take. Amalgamated Bank increased its stake in G1 Therapeutics by roughly $44,000 during the year’s first quarter to capitalize on a favorable market environment. During the second quarter, Virtu Financial LLC made a transaction that gave them a new stake in G1 Therapeutics. This new interest was estimated to be worth around $50,000. During the second quarter of 2018, Envestnet Asset Management Inc. purchased an additional 53,000 shares of G1 Therapeutics stock at about $53,000 per share.
During the second quarter, Centiva Capital LP began a new stake in G1 Therapeutics by investing about $58,000 in the firm. In the last development, Laurion Capital Management LP made a fresh investment in G1 Therapeutics during the second quarter. This new role is worth around $63,000 to the company. To the tune of 46.55 percent of the company’s stock, institutional investors and hedge funds collectively hold the company’s shares. G1 Therapies, Inc. is a biopharmaceutical company currently in the clinical stage of development.
The company’s primary focus is on the research, development, and marketing of small-molecule drugs for patients suffering from cancer. When COSELA is given to adult patients with advanced stage small cell lung cancer before a chemotherapy treatment that contains either platinum/etoposide or topotecan, it helps to lessen the severity of the myelosuppression that is caused by the chemotherapy.